A comprehensive analysis of common germline variants in TP53 confirmed genetic heterogeneity across AA and CA men for Arg72Pro and Pro47Ser variants and suggested that TP53 Arg72Pro predisposes men to clinically significant prostate cancer. This evidence concerns the gene TP53 and prostate carcinoma.